Responsible Development of New Technologies Critical in Complex, Connected World
By Andrew Maynard,
The Conversation
| 03. 04. 2015
Untitled Document
On July 31, 2012, a massive blackout swept across northeast India. At 1 pm local time, a power line in the state of Madhya Pradesh became overloaded and tripped out. As the supply grid struggled to pick up the slack, other lines went down. By 1:03, a cascading series of failures had pushed the electricity supply grid into a state of chaos, resulting in the largest blackout in human history. More than an estimated 600 million people lost power temporarily as a result of the collapse.
This blackout is a stark reminder of how vulnerable we all are to chaotic collapse around the many complex technological systems we rely on. Yet we continue to develop powerful new technologies at a rapid rate, with little thought as to how their very complexity and interconnectedness may cause them to unravel in the future.
The sheer audacity of our technological prowess is reflected in this year’s list of Top Ten Emerging Technologies from the World Economic Forum (WEF) – now in its fourth year. The list spans advances in genetic...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
